Personal clinical trial finder
Your search criteria - 50 result(s)
Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
The Ottawa Hospital, Ottawa, Ontario – Recruiting
Collection of Tissue Samples for Cancer Research
Study phase:
Recruitment status: Recruiting
Princess Margaret Hospital Cancer Centre, Toronto, – Completed
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
University Health Network - Princess Margaret Cancer Center, Toronto, Ontario – Active, not recruiting
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Study phase:
Recruitment status: Recruiting
Local Institution - 0065, Toronto, Ontario – Withdrawn
Local Institute, Toronto, Ontario – Recruiting
Local Institution - 0066, Toronto, Ontario – Completed
Other Centres
Local Institute, Weston, Ontario – Recruiting
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Study phase: Phase 1
Recruitment status: Recruiting
University of Calgary, Calgary, Alberta – Recruiting
Princess Margaret Cancer Center, Toronto, Ontario – Recruiting
Jewish General Hospital, Montreal, Quebec – Recruiting
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Study phase: Phase 2
Recruitment status: Recruiting
Cross Cancer Institute, Edmonton, Alberta – Recruiting
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia – Suspended
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia – Recruiting
Other Centres
Kingston Health Sciences Centre, Kingston, Ontario – Recruiting
London Regional Cancer Program, London, Ontario – Recruiting
Ottawa Hospital Research Institute, Ottawa, Ontario – Recruiting
University Health Network, Toronto, Ontario – Recruiting
The Jewish General Hospital, Montreal, Quebec – Recruiting
Allan Blair Cancer Centre, Regina, Saskatchewan – Recruiting
Saskatoon Cancer Centre, Saskatoon, Saskatchewan – Recruiting
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Study phase:
Recruitment status: Recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Cross Cancer Institute, Edmonton, Alberta – Recruiting
Vancouver General Hospital, Vancouver, British Columbia – Recruiting
CancerCare Manitoba, Winnipeg, Manitoba – Recruiting
Other Centres
QEII Health Sciences Centre, Halifax, Nova Scotia – Recruiting
Juravinski Cancer Centre, Hamilton, Ontario – Recruiting
London Health Sciences Centre, London, Ontario – Recruiting
The Ottawa Hospital, Ottawa, Ontario – Recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
Allan Blair Cancer Centre, Regina, Saskatchewan – Recruiting
Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients
Study phase: N/A
Recruitment status: Recruiting
London Health Sciences Centre-Victoria Hospital, London, Ontario – Recruiting
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Study phase: Phase 3
Recruitment status: Recruiting
BCCA-Vancouver Cancer Centre, Vancouver, British Columbia – Suspended
Atlantic Health Sciences Corporation-Saint John Regional Hospital, Saint John, New Brunswick – Suspended
Kingston Health Sciences Centre, Kingston, Ontario – Suspended
Other Centres
Lakeridge Health Oshawa, Oshawa, Ontario – Suspended
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
Study phase: Phase 1
Recruitment status: Recruiting
GSK Investigational Site, Edmonton, Alberta – Recruiting
GSK Investigational Site, London, Ontario – Completed
GSK Investigational Site, Ottawa, Ontario – Withdrawn
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
GSK Investigational Site, Edmonton, Alberta – Recruiting
GSK Investigational Site, Vancouver, British Columbia – Recruiting
GSK Investigational Site, Halifax, Nova Scotia – Recruiting
Other Centres
GSK Investigational Site, Toronto, Ontario – Recruiting
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
Study phase: Phase 2
Recruitment status: Recruiting
Tom Baker Cancer Centre, Calgary, Alberta – Recruiting
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Tom Baker Cancer Centre, Calgary, Alberta – Recruiting
Alberta Health Services, Edmonton, Alberta – Recruiting
Princess Margaret Cancer Centre University Health Network, Toronto, Ontario – Recruiting
Other Centres
McGill University Health Centre, Montreal, Quebec – Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 1
Recruitment status: Recruiting
Hamilton Health Sciences, Hamilton, Ontario – Recruiting
University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario – Recruiting
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Study phase: Phase 3
Recruitment status: Recruiting
Tom Baker Cancer Centre, Calgary, Alberta – Active, not recruiting
Vancouver General Hospital, Vancouver, British Columbia – Active, not recruiting
Juravinski Cancer Centre, Hamilton, Ontario – Active, not recruiting
Other Centres
Princess Margaret Cancer Centre University Health Network, Toronto, Ontario – Active, not recruiting
Hopital Maisonneuve-Rosemont, Montréal, Quebec – Active, not recruiting
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Cross Cancer Institute, Edmonton, Alberta – Recruiting
British Columbia Cancer Agency the Vancouver Centre, Vancouver, British Columbia – Recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
Other Centres
Jewish General Hospital, Montreal, Quebec – Recruiting
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Study phase: Phase 3
Recruitment status: Recruiting
Local Institution - 111, Calgary, Alberta – Completed
Local Institution - 103, Edmonton, Alberta – Completed
BC Cancer Agency, Fraser Valley Center, Surrey, British Columbia – Recruiting
Other Centres
Local Institution - 104, Saint John, New Brunswick – Completed
Memorial University of NewfoundlandDr. H Bliss Murphy Cancer Center, St John's, Newfoundland and Labrador – Recruiting
Queen Elizabeth Ii Health Sciences Centre, Halifax, Nova Scotia – Recruiting
Local Institution - 109, Ottawa, Quebec – Completed
Local Institution - 107, Saskatoon, Saskatchewan – Completed
CHU de Quebec-Universite Laval, Quebec, – Recruiting
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Study phase: Phase 3
Recruitment status: Recruiting
Tom Baker Cancer Center, Calgary, Alberta – Active, not recruiting
Cross Cancer Institute, Edmonton, Alberta – Active, not recruiting
QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia – Active, not recruiting
Other Centres
Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia – Active, not recruiting
Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario – Active, not recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Active, not recruiting
Jewish General Hospital, Montreal, Quebec – Active, not recruiting
CIUSSS de l'Est-de-l'Île-de-Montréal, Montréal, Quebec – Active, not recruiting
Saskatoon Cancer Center, Saskatoon, Saskatchewan – Active, not recruiting
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 2
Recruitment status: Recruiting
GSK Investigational Site, Oshawa, Ontario – Recruiting
GSK Investigational Site, Toronto, Ontario – Recruiting
GSK Investigational Site, Montreal, Quebec – Recruiting
Other Centres
GSK Investigational Site, Montréal, Quebec – Recruiting
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Study phase: Phase 2
Recruitment status: Recruiting
Tom Baker Cancer Center, Calgary, Alberta – Recruiting
The Ottawa Hospital - General Campus, Ottawa, Ontario – Recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Study phase: Phase 2
Recruitment status: Recruiting
Novartis Investigative Site, Calgary, Alberta – Active, not recruiting
Early Integration of Palliative and Supportive Care in Cellular Therapy
Study phase: N/A
Recruitment status: Recruiting
Tom Baker Cancer Centre, Calgary, Alberta – Recruiting
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
Study phase: Phase 1
Recruitment status: Recruiting
Princess Margaret Cancer Research Center/University Health Network, Toronto, Ontario – Recruiting
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
Study phase: Phase 3
Recruitment status: Recruiting
Tom Baker Cancer Center, Calgary, – Not yet recruiting
Cross Cancer Institute, Edmonton, – Not yet recruiting
McMaster University, Hamilton, – Recruiting
Other Centres
Hopital Maisonneuve-Rosemont, Montréal, – Not yet recruiting
Mcgill University Health Centre, Montréal, – Not yet recruiting
Ottawa Hospital Research Institute, Ottawa, – Not yet recruiting
(CHU) Centre Hospitalier Universitaire de Quebec Laval, Québec, – Not yet recruiting
Princess Margaret Cancer Centre, Toronto, – Not yet recruiting
Vancouver General Hospital, Vancouver, – Not yet recruiting
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Study phase: Phase 3
Recruitment status: Recruiting
Tom Baker Cancer Center, Calgary, Alberta – Recruiting
Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick – Recruiting
Saint John Regional Hospital, Saint John, New Brunswick – Recruiting
Other Centres
Hamilton Health Sciences Corporation, Hamilton, Ontario – Recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
Windsor Regional Hospital Cancer Program, Windsor, Ontario – Not yet recruiting
Centre Integre Universitaire de la Santé et de Services Sociaux de l'Est-de-l'ile-de-Montreal,, Montreal, Quebec – Recruiting
McGill University Health Centre, Montreal, Quebec – Recruiting
Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSS, Montreal, Quebec – Recruiting
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Alberta Health Services AHS - Foothills Medical Centre FMC, Calgary, Alberta – Recruiting
University of Alberta - Cross Cancer Institute, Edmonton, Alberta – Recruiting
University Health Network UHN - Princess Margaret Hospital PMH, Toronto, Ontario – Recruiting
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Study phase: Phase 3
Recruitment status: Recruiting
Investigational Site Number : 1240001, Toronto, Ontario – Recruiting
Investigational Site Number : 1240004, Greenfield Park, Quebec – Recruiting
Investigational Site Number : 1240003, Montreal, Quebec – Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Study phase: Phase 3
Recruitment status: Recruiting
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park, Quebec – Recruiting
Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSSS NÎM) - Hôpital du Sacré-Coeur, Montreal, Quebec – Recruiting
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus, Quebec City, Quebec – Recruiting
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Study phase: Phase 3
Recruitment status: Recruiting
QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia – Recruiting
Victoria Hospital & Children's Hospital - London Health Sciences Centre, London, Ontario – Recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
Other Centres
Local Institution - 0186, Montreal, Quebec – Withdrawn
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 3
Recruitment status: Recruiting
Tom Baker Cancer Centre, Calgary, Alberta – Recruiting
Saint John Regional Hospital, Saint John, New Brunswick – Recruiting
Brampton Civic Hospital, Brampton, Ontario – Recruiting
Other Centres
Lakeridge Health Oshawa, Oshawa, Ontario – Recruiting
CIUSSS de l'Est-de-l'Île-de-Montréal Installation Hôpital Maisonneuve-Rosemont, Montreal, Quebec – Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Study phase: Phase 3
Recruitment status: Recruiting
QEII Health Sciences Centre, Halifax, Nova Scotia – Recruiting
Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
Study phase:
Recruitment status: Recruiting
Edith Pituskin, Edmonton, Alberta – Recruiting
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 1
Recruitment status: Recruiting
Juravinski Cancer Centre /ID# 252053, Hamilton, Ontario – Recruiting
Ottawa Hospital Research Institute /ID# 252151, Ottawa, Ontario – Recruiting
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Study phase: Phase 1
Recruitment status: Recruiting
University Health Network (UHN) - Princess Margaret Cancer Centre (Princess Margaret Hospital), Toronto, Ontario – Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Study phase: Phase 3
Recruitment status: Recruiting
The Ottawa Hospital, Ottawa, Ontario – Recruiting
University Health Network (UHN) - Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Study phase: Phase 3
Recruitment status: Recruiting
Cross Cancer Institute, Edmonton, Alberta – Recruiting
The Ottawa Hospital - General Campus, Ottawa, Ontario – Recruiting
Local Institution - 0307, Montreal, Quebec – Not yet recruiting
Other Centres
CHUQ - The Hôtel-Dieu de Québec, Quebec, – Recruiting
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Study phase: Phase 3
Recruitment status: Recruiting
Local Institution - 0133, Edmonton, Alberta – Not yet recruiting
Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario – Recruiting
Local Institution - 0134, Montreal, Quebec – Not yet recruiting
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Hamilton Health Sciences, Hamilton, Ontario – Recruiting
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Study phase: Phase 4
Recruitment status: Recruiting
Tom Baker Cancer Center, Calgary, Alberta – Recruiting
Cross Cancer Institute, Edmonton, Alberta – Recruiting
McGill University Health Centre, Montréal, Quebec – Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Study phase: Phase 1/Phase 2
Recruitment status: Recruiting
Research Site, Hamilton, Ontario – Not yet recruiting
Research Site, Montreal, Quebec – Not yet recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Study phase: Phase 3
Recruitment status: Recruiting
The Moncton Hospital, Moncton, New Brunswick – Not yet recruiting
Jewish General Hospital, Montreal, Quebec – Not yet recruiting
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma
Study phase: Phase 3
Recruitment status: Recruiting
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario – Recruiting
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Study phase: Phase 3
Recruitment status: Recruiting
Juravinski Cancer Centre, Hamilton, Ontario – Recruiting
University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting
CIUSSS de l'Est-de-l'Île-de-Montréal Installation Hôpital Maisonneuve-Rosemont, Montreal, Quebec – Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Study phase: Phase 1
Recruitment status: Recruiting
Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick – Recruiting
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Study phase:
Recruitment status: Not yet recruiting
BC Cancer, Vancouver, British Columbia – ()
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Study phase: Phase 3
Recruitment status: Not yet recruiting
Local Institution - 0417, Calgary, Alberta – ()
Local Institution - 0423, Edmonton, Alberta – ()
Local Institution - 0402, London, Ontario – ()
Other Centres
Local Institution - 0395, Toronto, Ontario – ()
Local Institution - 0031, Montreal, Quebec – ()
Local Institution - 0098, Montréal, Quebec – ()
Prehab Prior to Stem Cell Transplantation in Multiple Myeloma
Study phase: N/A
Recruitment status: Not yet recruiting
University of Alberta/ Cross Cancer Institute, Edmonton, Alberta – ()
Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Study phase: Phase 2
Recruitment status: Recruiting
Local Institution - 0020, Calgary, Alberta – Not yet recruiting
Local Institution - 0021, Montréal, Quebec – Not yet recruiting
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Study phase: Phase 3
Recruitment status: Recruiting
Local Institution - 0133, Edmonton, Alberta – Not yet recruiting
Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario – Recruiting
Local Institution - 0134, Montreal, Quebec – Not yet recruiting